DOJ cuts deferred prosecution deal with bankrupt pharma

Pallavi Guniganti

04 December 2019

Credit: istock/okskaz

The Department of Justice’s antitrust division has charged Rising Pharmaceuticals with conspiring to fix prices and allocate customers for a generic hypertension drug, but resolved the charge with a deferred prosecution agreement.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Pallavi Guniganti

View full biography

Author

[email protected]

Tipline

In low Spirits: The Tipline for 6 December 2023
JetBlue’s lawyers had a lot to smile about during closing arguments. The judge presiding over the Department of Justice’s challenge to JetBlue/Spirit said he was “having problems" with blocking a deal in such a dynamic industry. But investors seemed less enthused. JetBlue’s stock dropped nearly 4% on Tuesday while Spirit’s fell more than 12% to $13.67 a share – a fraction of the $33.50 a share JetBlue committed to paying last June.
For St Pete’s Sake: The Tipline for 5 December 2023
Bidding adieu to bid competition: The Tipline for 4 December 2023

DOJ cuts deferred prosecution deal with bankrupt pharma

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Already have access? Login below

Related Topics

Pallavi Guniganti